唑来膦酸治疗乳腺癌骨相关疾病.ppt.pptVIP

* * * * * The addition of ZOL to neoadjuvant CT may influence pathologic response—exploratory evidence for direct antitumor activity in BC1 205 (6.1%) patients received neoadjuvant CT (104 CT, 101 CT + ZOL) Baseline characteristics and treatments were similar Median number of CT cycles and treatment duration were the same in both groups Median RITS was 30 mm (IQR, 7.5-60) in the CT group and 20.5 mm (IQR, 7-38.5) in the CT+ZOL group In a multivariate analysis (n = 171), ZOL, ER status and treatment duration were independent significant factors for RITS Adjusted mean RITS in CT and CT + ZOL groups were 42.4 mm and 28.2 mm, respectively; giving a difference in means of 14.1 mm (95% CI = 5.4, 22.9; P = .002) Pathologic complete response rate (breast and axilla) was 5.8% in the CT arm and 10.9% in the CT + ZOL arm (P = .033) Median number of positive lymph nodes following chemotherapy was 3 (IQR, 0-7) in the CT group and 2 (IQR, 0-5) in the CT + ZOL group (P = .629) The proportions of patients requiring mastectomy in the CT and CT + ZOL arms were 77.9% and 65.3%, respectively These data suggest a possible direct antitumor effect of ZOL in combination with neoadjuvant CT and warrants formal evaluation in prospective studies Reference: 1. Winter MC, et al. Presented at: 31st San Antonio Breast Cancer Symposium, December 10-14, 2008. San Antonio, Texas. Abstract 5101. * * * * Zheng等人在05年发表文章指出，与帕米膦酸比较，长期持续使用唑来膦酸能更有效的降低乳腺癌患者SRE的发生风险 * * * * Purpose 研究评估一线滤去This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate. Patients and Methods This prospective study evaluated the impact of second-line zoledronic acid on pain, quality of life, and markers of bone turnover (for example, urinary N-telopeptide [NTX]).